Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

In addition to the calls to cull or modify the passenger protections, IATA asked Trump to review the mandatory pilot ...

After months of uncertainty, Robert F. Kennedy Jr. took a major step toward confirmation as the next HHS secretary after the ...

Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...

“We are pleased to welcome HomeTrust Bancshares, Inc. to the New York Stock Exchange,” said Tara Dziedzic, Head of US Listings, New York Stock Exchange. “As an NYSE-listed company, HomeTrust joins our ...

UK efforts to guarantee energy security should focus on hydrogen rather than natural gas storage as the country moves to decarbonise power generation by 2030, according to Energy Secretary Ed ...

EXCLUSIVE: Republican Rep. Andy Barr’s decision on whether to run for U.S. Senate in Kentucky will be made "independent of the decisions that others make, including Sen. Mitch McConnell," he told Fox ...

The sources said that while Hamas has successfully recruited new members, many are young and untrained and are being used for ...

After creating 18 unicorns and mobilising Rs 90,000 Cr through its first Fund of Funds, the government is now focussing on ...

El Salvador has agreed to house violent US criminals and receive deportees of any nationality, in an unprecedented deal with ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

UN Secretary-General António Guterres described ... according to Gaza’s Ministry of Health, which does not differentiate between civilians and terrorists. Israel claims it has killed more ...